Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
kamuvudine K8
- Development stage
- Unknown
- Lead developer
- Inflammasome Therapeutics
- Modality
- Small Molecules
- Administration
- Implant, Intravitreal
01
Overview
Kamuvudine K8 (also known as K8 or Kamzinoflast) is an investigational small-molecule dual inflammasome inhibitor developed by Inflammasome Therapeutics. Derived from the nucleoside reverse transcriptase inhibitor (NRTI) scaffold, Kamuvudine K8 is engineered to retain anti-inflammasome activity while reducing antiviral activity and mitochondrial toxicity. It targets the NLRP3 and NLRC4 inflammasome pathways, blocking activation triggered by multiple toxic drivers such as complement, retrotransposons, and oxidative stress. Delivered as a bioerodible, sustained-release intravitreal implant administered once every three months directly into the back of the eye, Kamuvudine K8 is primarily being developed for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). In Phase 2 clinical trials, the 0.7 mg dose of K8 demonstrated a 54% reduction in GA lesion growth with a favorable safety profile, and a global Phase 3 pivotal program is planned.
- Other names
- Kamzinoflastkamuvudine-8kamuvudine8kamuvudine 8
02
Targets
NLRC4 (NLR family CARD domain containing 4)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on kamuvudine K8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on kamuvudine K8.